Tacrolimus Intrapatient Variability After Switching From Immediate or Prolonged-Release to Extended-Release Formulation, After an Organ Transplantation.

Del Bello, Arnaud; Gaible, Clotilde; Longlune, Nathalie; Hebral, Anne-Laure; Esposito, Laure; Gandia, Peggy; Kamar, Nassim

Del Bello, Arnaud; Gaible, Clotilde; Longlune, Nathalie; Hebral, Anne-Laure; Esposito, Laure; Gandia, Peggy; Kamar, Nassim.

Afiliación

Del Bello A; Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
Gaible C; INSERM U1043, IFR-BMT, CHU Purpan, Toulouse, France.
Longlune N; Université Paul Sabatier, Toulouse, France.
Hebral AL; Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
Esposito L; Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
Gandia P; Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.
Kamar N; Department of Nephrology and Organ Transplantation, CHU Rangueil, Toulouse, France.

Front Pharmacol ; 12: 602764, 2021.

Article en En | MEDLINE | ID: mdl-34690747

Palabras clave

extended-release tacrolimus; outcomes; rejection; solid organ transplantation; tacrolimus formulation; tacrolimus variability

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Año: 2021 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google